Latest Sales Guidance News

US Masters Residential Property Group reports a half-year profit and advances its ambitious asset sales program, while navigating a significant US tax structure change and mixed market conditions.

Whitehaven Coal reported a robust FY25 with underlying NPAT of $319 million and record production, while maintaining a strong balance sheet and announcing shareholder returns. The company’s FY26 guidance signals continued operational focus amid stabilizing coal markets.

Mount Gibson Iron reported a significant net loss for FY25 amid weaker iron ore prices but is pivoting towards gold with a major acquisition in the Northern Territory.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

Iluka Resources has met its full-year zircon-in-concentrate production guidance by mid-2025 while progressing key projects like Balranald and Eneabba amid ongoing global trade uncertainties.

Northern Star Resources has met its FY25 gold sales guidance with strong June quarter results and outlined an ambitious FY26 production and capital expenditure plan focused on growth and operational readiness.

Bowen Coking Coal has surpassed its full-year 2025 production and sales targets ahead of schedule while transitioning the Burton Mine Complex to an owner-operator model. However, ongoing market challenges and funding uncertainties cast a shadow over its near-term outlook.

Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

TerraCom Limited reported resilient coal sales of 1.6 million tonnes in Q3 2025 despite severe weather disruptions at Blair Athol, while advancing its Moorlands Thermal Coal Project with Wintime Energy.